Vasopharm Biotech Gmbh

Hoechst Aktiengesellschaft

Vasopharm Gmbh

Vasopharm Buitech Gmbh

Pascoe Pharmazeutische Präparate Gmbh

Harald Schmidt

Wolfgang Pfleiderer

Rainer Henning

Frank Tegtmeier

Peter Scheurer

Reinhard Schinzel

Lothar Fröhlich

Ulrich Walter

Kirstin Wingler

Ulrike Zabel

Wolfgang Poller

Peter Kotsonis

Shahriyar Taghavi-Moghadam

Georg Komesker

The invention relates to compounds of formula het-X-AB containing a N-heteroaryl moiety 'het', which is linked via X=sulfur to the 1,2,3-triazolo[4,5-d]pyrimidine-7-yl moiety AB of the formula (II).  The invention also relates to a process for the preparation of said compounds and the use thereof in drugs for the treatment of NAD(P)H oxidase-related diseases and disorders and inhibition of platelet activation.

Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation

The present invention relates to the use of pteridine derivatives of the formula Iin which X is O or NH and R, for example, is hydrogen, phenyl or the radical R&#x2014;CH&#x2014; and R, for example, is hydrogen, (C-C)-alkylmercapto, the radical &#x2014;NRRor the radical &#x2014;OR, and in which R, R, R, R, R, R, R, Rand Rhave the meanings given in claimwhich are nitric oxide synthase inhibitors, for the treatment of diseases which are caused by an increased nitric oxide level.

Use of tetrahydropteridine derivatives as no synthase inhibitors

The invention relates to the expression of the cDNA clone for sub-units a1 (hsGCa1) and b1 (hsGCb1) of human soluble guanylylcyclase and the subsequent purification of the active enzyme and use thereof, the medical application of the expression of this clone by gene transfer, in addition to antibodies against peptides derived from said sequence and the use thereof.

Isolated and purified human soluble guanylyl cyclase &#x3b1;1/&#x3b2;1 (hsgc&#x3b1;1/&#x3b2;1)

Compounds of formula (I), where preferably: A=a bridge of partial formula (II) or (III), Rand R=independently (substituted) alkyl, aryl or aralkyl, or together form a heterocycle, R=H, &#x2014;CO-Alkyl, or &#x2014;CO-Aryl, R=Aryl, &#x2014;CO&#x2014;O-Aryl or &#x2014;CO-Aryl and R=H, are potent inhibitors of NO-synthase and are suitable as pharmaceutical agents of prophylaxis and treatment of disease states associates with a disturbed NO metabolism.

N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent

Pteridine derivatives as no synthase inhibitors

Growing community of inventors

Giessen, Germany

Harald Schmidt